LONDON, January 18, 2013 /PRNewswire/ --
The patent cliff has seen many drug majors lose their exclusivity on blockbuster drugs to generic makers in the past years and this trend is expected to go for some years to come. In 2012 alone, over 40 branded drugs with a $35 billion yearly sales tag have lost patent protection. StockCall has technical coverage on two of the biggest generic makers, Mylan Inc. (NASDAQ: MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI), which is available for free upon registration at http://www.stockcall.com/report
The generic drug industry has been feasting on patent expirations in recent years, and if the start of 2013 is anything to go on, this year could see more of the same. Major branded drug companies have lost exclusivity rights to a number of top selling products, and generic alternatives, as well as customer's pockets, have been the main beneficiaries.
Mylan only recently announced that it is now releasing its generic of Pfizer's Dilantin tablets after receiving the FDA's seal of approval. Dilantin is given for the control of generalized tonic-clonic (i.e., grand mal) and complex partial (i.e., psychomotor, temporal lobe) seizures, and prevention and treatment of seizures occurring during or following neurosurgery. According to IMS Health, the 50 mg chewable tablet saw U.S. sales of close to $16.5 million for a 12 month period ending September 30, 2012. See our technical analysis on Mylan by sign up now at http://www.StockCall.com/MYL011813.pdfAlso in news lately has been Watson Pharmaceuticals Inc.'s [ Free Analysis Report on WPI] [ (1) ] generic version of Ferring Pharmaceuticals' Lysteda tablet which received the FDA's approval even as an infringement lawsuit against Watson Pharma has been filed by the original maker of the drug. Whilst this legal battle is still pending, Watson Pharma intends to make the most of the time to launch its generic version. Last year, Lysteda saw revenues of close to $25 million in the U.S. Generic companies also currently have an impressive list of abbreviated new drug applications awaiting FDA approval. Those that have first-to-file status have the potential to be even more lucrative as these companies can enjoy a period of generic exclusivity that is usually 180 days.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV